Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Cancer Discov. 2012 Feb;2(2):112-4. doi: 10.1158/2159-8290.CD-11-0350.
In this issue of Cancer Discovery, Bellail and colleagues unravel how overexpression of the ubiquitin-modifying enzyme A20 results in TNF-related apoptosis-inducing ligand (TRAIL) resistance in glioblastoma. After TRAIL receptor stimulation, A20 mediates the polyubiquitination of RIP1 at the TRAIL receptor tail, resulting in the interaction of the polyubiquin chain to procaspase-8 that is recruited to the TRAIL-bound receptors. The inability of ubiquitin-bound procaspase-8 to be dimerized and activated prevents the execution of the apoptotic program.
在本期《Cancer Discovery》中,Bellail 及其同事揭示了泛素修饰酶 A20 的过表达如何导致胶质母细胞瘤对 TNF 相关凋亡诱导配体(TRAIL)产生耐药性。在 TRAIL 受体刺激后,A20 介导 RIP1 在 TRAIL 受体尾部的多泛素化,导致多泛素链与募集到 TRAIL 结合受体的 procaspase-8 相互作用。结合泛素的 procaspase-8 不能二聚化和激活,从而阻止了凋亡程序的执行。